Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.
- Status
- WITHDRAWN
- Phase
- PHASE3
Clinical Trials Related to Perjeta
Related studies linked through entity extraction aliases.
Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers
- Status
- UNKNOWN
- Phase
- PHASE1
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
- Status
- COMPLETED
- Phase
- PHASE1
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2